Resources

oncology

CONTENT HIGHLIGHT

Drug discovery to clinical trials in five years

Read our Proof-of-concept study that demonstrates how HUB Organoids can streamline the entire preclinical drug development process, resulting in significant savings in time, cost, and resources.

Fact sheets

On-demand webinars

Posters

Case studies

White papers

HUB's blog

Blog

Ask the Expert: Inside the inFOCUS Assay for IBD Drug Discovery

Learn how this assay uncovers key disease mechanisms, supports drug target discovery, and opens new doors for collaborative IBD drug...

Blog

The KRAS Conundrum: Challenges and strategies for targeted therapies in cancer

KRAS is a proto-oncogene that is crucial in regulating cell growth and division. Mutations in the KRAS gene are commonly...

Blog

Ask the Expert: How can patient-derived organoids accelerate KRAS drug development?

RAS proteins have been considered undruggable for several reasons. First, they have a very smooth surface without well-defined binding pockets,...

Info sheets

Key publications

HUB Organoids

Drug discovery to clinical trials in five years

Explore our resource portfolio

Fact sheets

Transforming T cell therapy for solid tumors using patient-derived HUB Organoids®

Application of HUB Organoids in immuno-oncology drug development

Tumor organoids

On-demand webinars

Minimizing Oncology Drug Failure Rates Using Organoid Modeling and Multi-omic Data

Mini-Organs, Major Breakthroughs: Accelerating Oncology Drug Development

10 years of breakthroughs in Organoid Technology: from adult stem cell discovery to changing patients’ lives

Posters

Patient-Derived Airway Organoids for Modelling Rhinovirus Infection

3D In-Vitro Fibroblast-Patient Derived Organoid Co-Culture: A High-Throughput Platform for Inflammatory Bowel Disease Drug Development

Reconstructing tumor microenvironment with patient-derived organoids for derisking Immuno-Oncology therapies

Patient-derived organoids as a reliable screening platform for assessing ADC efficacy and specificity

Resistant PDO models: Unraveling drug resistance mechanisms for discovering new drug targets

Patient-derived organoids: A pre-clinical model to assess infection and killing capacity of viral vectors for cancer therapy

Case studies

Advancing immunotherapy for solid tumors with patient-derived organoids

Drug discovery to clinical trials in five years

White papers

Accelerating oncology drug discovery with HUB Organoids®

HUB's blog

Ask the Expert: Inside the inFOCUS Assay for IBD Drug Discovery

The KRAS Conundrum: Challenges and strategies for targeted therapies in cancer

Ask the Expert: How can patient-derived organoids accelerate KRAS drug development?

Info sheets

HUB Organoids in Preclinical Toxicology

PDO Monolayer for Inflammatory Bowel Disease (IBD)

De-risk your immuno-oncology drug development with HUB Organoids®

Key publications

Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response

Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer

Intestinal organoids as an in vitro platform to characterize disposition, metabolism, and safety profile of small molecules

Application of human liver organoids as a patient-derived primary model for HBV infection and related hepatocellular carcinoma

Targeting G542X CFTR nonsense alleles with ELX-02 restores CFTR function in human-derived intestinal organoids

Organoid-Derived Epithelial Monolayer: A Clinically Relevant In Vitro Model for Intestinal

Have any questions?